Deutsche Bank’s Protalix BioTherapeutics PLX Stock Holding History

Deutsche Bank’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$181K	Buy	77,537 +2,552	+3%	+$5.4K	﹤0.01%	3306
2026 Q1	$163K	Buy	74,985 +74,139	+8,763%	+$184K	﹤0.01%	3090
2025 Q4	$1.52K	Sell	846 -64,771	-99%	-$132K	﹤0.01%	3592
2025 Q3	$146K	Buy	+65,617	New	+$107K	﹤0.01%	3204
2021 Q3	–	Sell	-873	Closed	-$2K	–	4611
2021 Q2	$2K	Buy	+873	New	+$3K	﹤0.01%	4549
2017 Q3	–	Sell	-33,057	Closed	-$276K	–	5032
2017 Q2	$276K	Sell	33,057 -7,562	-19%	-$71K	﹤0.01%	3760
2017 Q1	$552K	Buy	40,619 +9,519	+31%	+$85.6K	﹤0.01%	3029
2016 Q4	$138K	Hold	31,100	–	–	﹤0.01%	3900
2016 Q3	$177K	Sell	31,100 -8	-0%	-$50	﹤0.01%	3712
2016 Q2	$199K	Sell	31,108 -20	-0.1%	-$160	﹤0.01%	3777
2016 Q1	$261K	Sell	31,128 -493	-2%	-$4.22K	﹤0.01%	3527
2015 Q4	$322K	Buy	31,621 +30,541	+2,828%	+$311K	﹤0.01%	3481
2015 Q3	$12K	Buy	+1,080	New	+$17.2K	﹤0.01%	4914
2015 Q1	–	Sell	-148	Closed	-$2K	–	5751
2014 Q4	$2K	Sell	148 -26,211	-99%	-$563K	﹤0.01%	6013
2014 Q3	$637K	Buy	+26,359	New	+$759K	﹤0.01%	3327

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Deutsche Bank's PLX Position: Q2 2026 in Review

Deutsche Bank increased its Protalix BioTherapeutics (PLX) stake by 3.4% in Q2 2026, buying an estimated $5.4K and bringing the position to 77,537 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #3306.

Deutsche Bank first reported a position in PLX in Q3 2014 and has held it in 15 quarters since. The position peaked at $637K in Q3 2014. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Deutsche Bank held 77,537 shares of Protalix BioTherapeutics worth $181K as of Q2 2026.
Deutsche Bank bought 2,552 Protalix BioTherapeutics shares in Q2 2026, an estimated $5.4K.
Protalix BioTherapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #3306 holding.
Deutsche Bank first reported a position in Protalix BioTherapeutics in Q3 2014 and has held it in 15 quarters since.
Deutsche Bank's Protalix BioTherapeutics position peaked at $637K in Q3 2014.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.